Another NICE Drug
In recently published draft guidance NICE has approved the routine use of another drug combination for some people with secondary breast cancer. Palbociclib, also known as Ibrance, is a targeted drug made by Pfizer and is now recommended in combination with fulvestrant for the treatment of hormone receptor positive HER2 negative secondary breast cancer when…
